Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 5Carcinoma, Non-Small-Cell Lung 5Rhabdomyosarcoma 4Prostatic Neoplasms 4Osteosarcoma 3Neoplasms 3Sarcoma, Synovial 2Sarcoma, Ewing 2Neuroectodermal Tumors, Primitive, Peripheral 2Neoplasm Metastasis 2Lung Neoplasms 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Adrenocortical Carcinoma 2Wilms Tumor 1Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Retinoblastoma 1Rectal Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Neuroectodermal Tumors 1Neuroblastoma 1Mesothelioma, Malignant 1Liver Neoplasms 1Liposarcoma 1Leiomyosarcoma 1

Interventions

Gemcitabine 13Doxorubicin 8Docetaxel 7Trabectedin 5pazopanib 4Nivolumab 4Temozolomide 3Specimen Handling 3Sorafenib 3rucaparib 2pembrolizumab 2liposomal doxorubicin 2durvalumab 2brostallicin 2Sunitinib 2Radiotherapy 2Radiation Dose Hypofractionation 2Magnetic Resonance Spectroscopy 2Letrozole 2Ifosfamide 2Dacarbazine 2Bevacizumab 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tremelimumab 1talimogene laherparepvec 1sotigalimab 1soblidotin 1saracatinib 1rubitecan 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leiomyosarcoma × cixutumumab × Clear all
NCT00668148 2018-07-17

A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma

Eli Lilly and Company

Phase 2 Completed
113 enrolled 13 charts
Sarcoma

Leiomyosarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Peripheral, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡